B+
Bull case
25%
Probability
Target price
$4.10
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
NRXP
NRXDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
A timely ketamine ANDA approval could turn completed manufacturing validation into a commercial launch, while the DARPA-funded study provides a distinct longer-term clinical opportunity.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +7.3.
What can break
NRX-100's real-world-evidence strategy still requires a completed NDA and FDA review.
Momentum
32
Value
41
Sentiment
49
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.25 · Bull $4.10 · Bear $1.25Analysis 2026-10-21; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-29 • Vendor: Data Vendor v1
Scores
As of 2026-10-28 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-21 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-28
Investment thesis
As of 2026-10-28
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-28. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $38.50
Why
Momentum32 · Δ7d -2.4
Value41 · Δ7d -0.1
Sentiment49 · Δ7d +7.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +7.3.
Contradictions & invalidation
- • NRX-100's real-world-evidence strategy still requires a completed NDA and FDA review.
- • The June 2026 10-Q reported a $4.7 million working-capital deficit and substantial doubt about going-concern status; additional equity could dilute holders. [#10-Q-2026-08-14] SEC 10-Q
- • Regulatory timing remains uncertain, the NRX-100 path is unfinished, and clinical expansion may require more capital.
Catalyst clock
2026-11-10
Preservative-free ketamine ANDA decision
Lead driver: Sentiment · See AI snapshot
Momentum
32
8% active weight
Current posture
7d trendImproving
Δ7d
-2.4
Δ21d
+26.1
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
49
45% active weight
Current posture
7d trendImproving
Δ7d
+7.3
Δ21d
+11.3
Why this grade
Composite grade D. Momentum 32.1 / Value 40.6 / Sentiment 49.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-21. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$2.25
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.25
Analysis reference price unavailable
Analysis 2026-10-21 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-29
Fundamentals (TTM)
As of 2026-10-29
Market Cap
$115.17M
Beta
1.92
Shares Out
43.3M
P/E (TTM) · Derived
-2.0
P/S (TTM)
279.82
P/FCF (TTM) · Derived
-4.16
Rev YoY
-
EPS YoY
-55.2%
Gross Margin
+32.7%
Op Margin
-588.1%
Net Debt
-$7.17M
Current Ratio
0.86
As of 2026-10-28 • Updated nightlySource: Internal modelMethods & Data